Tests pulsed electric field treatment for lung tumors
Tests pulsed electric field ablation in adults with early lung cancer.
Key facts
- Who runs it
- Energenx Medical LTD.
- Where
- Shanghai, ChinaSee the site
- Trial code
- Registry title
- Clinical Trial to Evaluate the Efficacy and Safety of Pulsed Electric Field Ablation Devices in the Treatment of Lung Tumors
- Status
- Recruiting
- People taking part
- 126 people, planned
- Started
- 25 Dec 2024
- Expected to end
- 25 Aug 2027
- Type of study
- Interventional
- Treatments tested
- PEF Treatment
- Record updated
- 21 August 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with early-stage non-small cell lung cancer who have small lung tumors that can be treated with ablation using a pulsed electric field device.
- Age
- 18 years or older
- Sex
- All sexes can join
- Disease stage
- Non-small cell lung cancer confirmed by pathology. The largest tumor is 3 cm (1.2 in) or smaller. There are no more than 3 tumors. The summary describes early-stage tumors that cannot be removed by surgery.
- Earlier treatment
- People taking blood thinners or antiplatelet drugs must have stopped them before ablation, within the prescribed safety period. People who took part in another clinical trial within the last three months cannot join.
Main reasons for not taking part
- Cannot have or refuses general anesthesia
- Cannot have or refuses bronchoscopy
- Active implants in the chest or metal implants in the lung to be treated
- Blood clotting problems that cannot be corrected, or platelets below 50×10^9/L
- Pregnant or breastfeeding women, or women planning pregnancy during the study
The registry criteria, word for word
Show all 5 criteriaShow less
Who can take part
- Age ≥ 18 years old; 2. Pathological diagnosis of non-small cell lung cancer, with the maximum diameter of the tumor ≤ 3 cm and the number ≤ 3; 3. ECOG score ≤ 2 points; 5. According to the evaluation of the researcher, it is technically feasible to perform ablation treatment on the lesion; 6. The subject agrees to receive ablation treatment and signs the informed consent form
Who cannot take part
- Has a history of severe allergic reactions
- Has active implants in the chest cavity or metal implants in the lung to be treated; 6. Uncorrectable coagulation abnormalities (INR>1.5 or APTT>1.5 ULN), with bleeding tendency; anticoagulant therapy and/or antiplatelet drugs are discontinued before ablation for no longer than the prescribed safety period; platelets <50×10\^9/L; 7. Severe liver and kidney dysfunction, assessed by the researchers as unsuitable for inclusion; 8. Accompanied by infectious diseases that cannot be effectively controlled; 9. Subjects with other severe lung diseases (including severe interstitial pneumonia, pulmonary fibrosis, pulmonary fibrosis combined with emphysema, atelectasis, etc.), assessed by the researchers as unsuitable for inclusion 10. Acute cardiovascular and cerebrovascular accidents such as acute cerebral infarction, acute coronary syndrome, etc. within 3 months; 11. Subjects with severe cardiac dysfunction; history of severe arrhythmias in the past 2 years, including rapid atrial arrhythmias, any rapid ventricular arrhythmias; history of II degree type II or III degree atrioventricular block; and sinus bradycardia with a heart rate of less than 45 beats per minute, etc.; 12. Subjects have participated in or are participating in other clinical trials within three months; 13. Pregnant, lactating women, or women who plan to become pregnant during the study; 14. Subjects determined by the researchers to have other conditions that are unsuitable for inclusion
- The subject cannot tolerate or refuses general anesthesia
- Has contraindications to bronchoscopy or refuses bronchoscopy
Where in China
- Shanghai Chest Hospital, Shanghai Jiao Tong University School of Medicine,Shanghai, ChinaContact: Jiayuan Sun, M.D., PhD.Taking people
About the trial
What the trial wants to find out
The goal of this clinical trial is to verify the efficacy and safety of pulsed electric field (PEF) treatment of early-stage unreseectable non-small cell lung cancer(NSCLC) patients.
Read full original descriptionShow less
The main questions it aims to answer are:
* Safety of PEF treatment of early-stage unreseectable NSCLC patients. * Locoregional control of ablated lesions. * Survival and quality of life assessment of early-stage unreseectable NSCLC patients.
The group in the trial
- PEF TreatmentTreatment being tested
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- A Multi-center, Single-group Clinical Trial to Evaluate the Efficacy and Safety of Pulsed Electric Field (PEF) Ablation Devices in the Treatment of Lung Tumors
- Plain-language title
- Tests pulsed electric field treatment for lung tumorsGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Record updated
- 21 August 2026